معرفی
Professor Phillip Darcy is an Adjunct Associate Professor and NHMRC Senior Research Fellow at the Peter MacCallum Cancer Centre, affiliated with Monash University. His research focuses on developing CAR T-cell therapies for cancer treatment, with a particular emphasis on preclinical models and clinical translation. He leads a laboratory that engineers gene-modified T-cells expressing chimeric antigen receptors (CARs) to target cancers such as acute myeloid leukemia and non-small cell lung carcinoma. Recent clinical trials, including a Phase I trial for AML patients, mark Australia's first use of this approach. His work also explores combined immune therapies to enhance cancer treatment efficacy.
Dr. Darcy has contributed to over 79 research outputs, including studies on tumor microenvironment modulation and overcoming immune checkpoint limitations. He is actively involved in collaborative projects such as 'Developing novel CAR T cell therapy approaches to treat prostate cancer' (2022–2025) and 'Targeting Immune Checkpoints In Obesity-Driven HCC' (2021–2023). His research addresses UN Sustainable Development Goals related to health and well-being.
- Key Projects:
- Developing CAR T-cell therapies for prostate cancer (2022–2025)
- Investigating immune checkpoints in obesity-driven liver cancer (2021–2023)
- Awards: NHMRC Senior Research Fellowship
- Grants/Advising: Leads multiple grants focused on cancer immunotherapy and collaborates with institutions like the University of Melbourne and Alfred Hospital.
His lab’s advancements in CAR T-cell engineering have been highlighted in Cell Reports, Nature Communications, and Cancer Discovery. Ongoing clinical trials and translational research aim to bridge preclinical discoveries with patient care.
